Glaxo Group Limited

Stephen John Skittrall

Derek L Crookes

Joanne Craig

Malcolm Brian Berry

Mark Jason Hughes

David Parry-Jones

A novel process for preparing a compound of formula (I) which comprises converting a compound of formula (II) to a compound of formula (I) via a compound of formula (III), or a salt thereof, without isolating any intermediates.

Process for the preparation of 6-&#x3b1;,9-&#x3b1;-difluoro-17-&#x3b1;-((2-furanylcarbonyl)oxy)-11-&#x3b2;-hydroxy-16-&#x3b1;-methy1-3-oxo-androsta-1,4-diene-17-&#x3b2;- -carbothioic acid S-fluoromethyl

The present invention, relates to 3-�2-(dimethylamino)ethyl!-N-methyl-1H-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof, and to pharmaceutical compositions containing same. The compound is useful in the treatment of conditions associated with cephalic pain, in particular migraine. The pharmaceutical compositions are particularly useful as intranasal formulations.

Medicaments

3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof are disclosed. The compound is of use in the preparation of pharmaceutical compositions, particularly for intranasal formulations, for use in the treatment of conditions associated with cephalic pain, in particular migraine.

Growing community of inventors

Ware, United Kingdom

Stephen John Skittrall